Results 11 to 20 of about 100,658 (276)

Etiology and Outcomes of Thrombotic Microangiopathies.

open access: yesClin J Am Soc Nephrol, 2019
BACKGROUND AND OBJECTIVES Thrombotic microangiopathies constitute a diagnostic and therapeutic challenge. Secondary thrombotic microangiopathies are less characterized than primary thrombotic microangiopathies (thrombotic thrombocytopenic purpura and ...
Bayer G   +21 more
europepmc   +2 more sources

Ten tips for managing complement-mediated thrombotic microangiopathies (formerly atypical hemolytic uremic syndrome): narrative review [PDF]

open access: yesBMC Nephrology
Complement-mediated thrombotic microangiopathies (CM-TMA) are rare and life-threatening disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ damage.
Pilar Musalem
doaj   +2 more sources

Complement Activation and Thrombotic Microangiopathies.

open access: yesClin J Am Soc Nephrol, 2019
BACKGROUND AND OBJECTIVES Atypical hemolytic uremic syndrome is a form of thrombotic microangiopathy caused by dysregulation of the alternative complement pathway. There is evidence showing complement activation in other thrombotic microangiopathies. The
Palomo M   +36 more
europepmc   +2 more sources

Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. [PDF]

open access: yesFront Immunol, 2019
Thrombotic microangiopathies (TMAs) are a heterogeneous group of syndromes presenting with a distinct clinical triad: microangiopathic hemolytic anemia, thrombocytopenia, and organ damage.
Gavriilaki E   +2 more
europepmc   +2 more sources

An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. [PDF]

open access: yesClin Kidney J, 2019
Conditions presenting with signs of thrombotic microangiopathies (TMAs) comprise a wide spectrum of different diseases. While pathological hallmarks are thrombosis of arterioles and capillaries, clinical signs are mechanical haemolysis, thrombocytopenia ...
Aigner C   +3 more
europepmc   +2 more sources

Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus. [PDF]

open access: yesAdv Chronic Kidney Dis, 2019
Antiphospholipid syndrome (APS) and other causes of thrombotic microangiopathy (TMA) negatively impact the renal outcomes of patients with systemic lupus erythematosus (SLE) and lupus nephritis.
Kotzen ES, Roy S, Jain K.
europepmc   +2 more sources

Influenza-associated thrombotic microangiopathies. [PDF]

open access: yesPediatr Nephrol, 2018
Thrombotic microangiopathy (TMA) refers to phenotypically similar disorders, including hemolytic uremic syndromes (HUS) and thrombotic thrombocytopenic purpura (TTP). This review explores the role of the influenza virus as trigger of HUS or TTP.
Bitzan M, Zieg J.
europepmc   +2 more sources

Editorial: Thrombotic Microangiopathies, Diagnostic and Therapeutic Advances [PDF]

open access: yesFrontiers in Medicine, 2021
Robert W. Maitta   +3 more
doaj   +2 more sources

Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies [PDF]

open access: bronzeBritish Journal of Haematology, 2012
Marie Scully   +7 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy